N-glycolyl GM3 ganglioside (Neu5GcGM3) (Neu5GcGM3)

N-glycolyl GM3 ganglioside (Neu5GcGM3) is a sialic acid-containing glycosphingolipid that serves as a prominent tumor-associated carbohydrate antigen (TACA) [1, 3]. While humans cannot synthesize the N-glycolylneuraminic acid (Neu5Gc) precursor due to an evolutionary mutation in the CMAH gene, human cancer cells can metabolically incorporate it from dietary sources [5, 6]. This results in the selective expression of Neu5GcGM3 on the surface of various malignancies, such as non-small cell lung cancer, breast cancer, and melanoma, while it remains largely absent from normal human tissues [2, 5, 10]. The recognition of Neu5GcGM3 by the receptor CD169 (Siglec-1) on macrophages is a critical interaction that facilitates the capture of tumor-derived extracellular vesicles and influences the immune landscape of the tumor microenvironment [1, 5, 13]. Because of its status as a neoantigen, Neu5GcGM3 is a major target for immunotherapy, including the anti-idiotype vaccine Racotumomab and the monoclonal antibody 14F7 [3, 4, 10]. These therapies aim to overcome the low immunogenicity of carbohydrate antigens to trigger a specific anti-tumor immune response [3, 7]. Monitoring Neu5GcGM3 expression and the induction of specific antibodies serves as a biomarker for treatment efficacy in clinical settings [10, 12].

Other names

NGcGM3N-glycolylneuraminic acid-containing GM3Neu5Gc-GM3Hanganutziu-Deicher antigenNGcGM3-VSSP

Induction of a specific immune response against Neu5GcGM3-expressing cells via anti-idiotype vaccine mechanisms or direct monoclonal antibody-mediated cytotoxicity.